Klacid – postmarketing observational study in patients with serious community-acquired pneumonia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00000025

Enrollment

Registered

2008-09-05

Start date

2003-01-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

serious community-acquired pneumonia J18

Interventions

Group 1: Klacid® therapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - One of these three signs: fever, purulent sputum, typical auscultation findings - An infiltration in X-ray - Start of anti-infective therapy with Klacid within 24 hours after admission - The diagnosis is: community acquired

Exclusion criteria

Exclusion criteria: - Pretreatment with Klacid - Transfer from another hospital

Design outcomes

Primary

Measure	Time frame
The use of Klacid® will be documented in a high number of patients under conditions simulating practical use. Rare adverse effects shall be traced or previously known good tolerability of the drug shall be confirmed. An additional goal is to collect further data on efficacy and also the rapid onset of action.	—

Countries

Germany

Contacts

Public ContactFranz Daschner

Institut für Umweltmedizin und Krankenshaushygiene Universitätsklinik Freiburg

Franz.Daschner@uniklinik-freiburg.de

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026